148 related articles for article (PubMed ID: 24483347)
41. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma.
Alexanian R; Weber D; Giralt S; Dimopoulos M; Delasalle K; Smith T; Champlin R
Bone Marrow Transplant; 2001 May; 27(10):1037-43. PubMed ID: 11438818
[TBL] [Abstract][Full Text] [Related]
42. Multiple myeloma.
Smith D; Yong K
BMJ; 2013 Jun; 346():f3863. PubMed ID: 23803862
[No Abstract] [Full Text] [Related]
43. Simple variables predict survival after autologous transplantation: a single centre experience in 181 multiple myeloma patients.
Krejci M; Hajek R; Buchler T; Krivanova A; Svobodnik A; Pour L; Adam Z; Mayer J; Vorlicek J
Neoplasma; 2007; 54(2):143-8. PubMed ID: 17319788
[TBL] [Abstract][Full Text] [Related]
44. Molecular and clinical follow-up after treatment of multiple myeloma.
Rasmussen T; Knudsen LM; Huynh TK; Johnsen HE
Acta Haematol; 2004; 112(1-2):105-10. PubMed ID: 15179010
[TBL] [Abstract][Full Text] [Related]
45. Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions.
Graziani MS; Merlini G
Expert Rev Mol Diagn; 2014 Jan; 14(1):55-66. PubMed ID: 24308339
[TBL] [Abstract][Full Text] [Related]
46. [Serum free light chains for diagnosis and follow-up of multiple myeloma].
Jung S; Kim M; Lim J; Kim Y; Han K; Min CK; Min WS
Korean J Lab Med; 2008 Jun; 28(3):169-73. PubMed ID: 18594166
[TBL] [Abstract][Full Text] [Related]
47. Recent advances in the management of multiple myeloma.
Kumar L; Verma R; Radhakrishnan VR
Natl Med J India; 2010; 23(4):210-8. PubMed ID: 21192514
[TBL] [Abstract][Full Text] [Related]
48. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
[TBL] [Abstract][Full Text] [Related]
49. Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.
Siegel DS; Vij R; Jakubowiak AJ
Clin Adv Hematol Oncol; 2011 Apr; 9(4):1-15. PubMed ID: 21928467
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response.
Martínez-Sánchez P; Montejano L; Sarasquete ME; García-Sanz R; Fernández-Redondo E; Ayala R; Montalbán MA; Martínez R; García Laraña J; Alegre A; Hernández B; Lahuerta JJ; Martínez-López J
Br J Haematol; 2008 Sep; 142(5):766-74. PubMed ID: 18637804
[TBL] [Abstract][Full Text] [Related]
51. The Diagnosis and Treatment of Multiple Myeloma.
Gerecke C; Fuhrmann S; Strifler S; Schmidt-Hieber M; Einsele H; Knop S
Dtsch Arztebl Int; 2016 Jul; 113(27-28):470-6. PubMed ID: 27476706
[TBL] [Abstract][Full Text] [Related]
52. Serum free light chains for monitoring multiple myeloma.
Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
[TBL] [Abstract][Full Text] [Related]
53. New questions about transplantation in multiple myeloma.
Hari P; Pasquini MC; Vesole DH
Oncology (Williston Park); 2006 Sep; 20(10):1230-42; discussion 1242, 1244, 1249-50. PubMed ID: 17024872
[TBL] [Abstract][Full Text] [Related]
54. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.
Martínez-López J; Paiva B; López-Anglada L; Mateos MV; Cedena T; Vidríales MB; Sáez-Gómez MA; Contreras T; Oriol A; Rapado I; Teruel AI; Cordón L; Blanchard MJ; Bengoechea E; Palomera L; de Arriba F; Cueto-Felgueroso C; Orfao A; Bladé J; San Miguel JF; Lahuerta JJ;
Blood; 2015 Aug; 126(7):858-62. PubMed ID: 26089396
[TBL] [Abstract][Full Text] [Related]
55. Kidney disease and multiple myeloma.
Heher EC; Rennke HG; Laubach JP; Richardson PG
Clin J Am Soc Nephrol; 2013 Nov; 8(11):2007-17. PubMed ID: 23868898
[TBL] [Abstract][Full Text] [Related]
56. Multiple myeloma.
Palumbo A; Anderson K
N Engl J Med; 2011 Mar; 364(11):1046-60. PubMed ID: 21410373
[No Abstract] [Full Text] [Related]
57. Multiple myeloma: a new treatment paradigm.
ONS News; 2004; 19(9 Suppl):79-80. PubMed ID: 15478600
[TBL] [Abstract][Full Text] [Related]
58. Serological normalisation as a surrogate marker for minimal residual disease negativity in multiple myeloma.
Campbell L; Panitsas F; Basu S; Anyanwu F; Lee S; Ferry B; Ramasamy K
Br J Haematol; 2019 May; 185(4):775-778. PubMed ID: 30338523
[No Abstract] [Full Text] [Related]
59. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains.
Dawson MA; Patil S; Spencer A
Haematologica; 2007 Jan; 92(1):143-4. PubMed ID: 17229655
[TBL] [Abstract][Full Text] [Related]
60. Multiple myeloma.
Chavda SJ; Yong K
Br J Hosp Med (Lond); 2017 Feb; 78(2):C21-C27. PubMed ID: 28165783
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
